Pediatric Targeted Therapy denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for pediatric targeted therapy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied This Claim — and Why You Can Appeal

A prior authorization denial from BCBS for a pediatric targeted therapy usually results from one of three situations: the medication was dispensed before PA was obtained; the PA request was submitted but denied due to incomplete or missing documentation; or the prescriber's submission did not address all of BCBS's specific clinical criteria for this drug class. PA denials for pediatric targeted therapies are among the most reversible when the appeal is submitted with complete clinical documentation directly tied to each criterion in BCBS's coverage policy. The underlying clinical appropriateness of the therapy is often not in genuine dispute — the issue is matching the documentation to the policy's checklist.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): File a written internal appeal within the deadline stated on your denial notice. BCBS must conduct a full-and-fair review with a clinician reviewer who has relevant pediatric expertise.
• Concurrent peer-to-peer review: Request a peer-to-peer call between the treating pediatric specialist and the BCBS medical director simultaneously with the formal appeal. This often resolves PA denials faster than the written process alone.
• External review (ACA §2719): After final internal denial, you have approximately four months to file with an independent review organization.
• Expedited option: For pediatric serious illness, expedited internal and external review should be requested whenever delay poses a clinical risk. Expedited decisions are typically due within 72 hours.

## Documentation to Gather

1. BCBS PA criteria for this drug — request BCBS's full PA criteria and coverage policy for the specific agent in writing before submitting the appeal. Your appeal letter should address each criterion explicitly. 2. Prescriber's medical-necessity letter — the treating pediatric specialist should address each PA criterion point by point, linking every requirement to a specific chart fact, date, or test result. 3. Diagnosis and molecular confirmation — pathology, genomic, or biomarker reports confirming the diagnosis and the specific target or indication. 4. Prior treatment history — if BCBS requires step therapy, document prior treatments with dates, responses, and outcomes from the medical record. 5. Clinical severity documentation — chart notes, staging information, or specialist evaluations demonstrating the seriousness of the child's condition and the urgency of treatment. 6. FDA prescribing label — confirms that the prescribed use falls within or is consistent with the labeled indication.

## Criteria-Mapping Structure for Your Appeal Letter

| BCBS PA criterion | Chart-based documentation | |---|---| | Diagnosis confirmed with appropriate testing | Pathology / molecular report [date from chart] | | Prescriber specialty requirement met | Treating physician credentials and subspecialty | | Prior therapy requirement satisfied | Medication history with dates and outcomes | | Clinical severity threshold documented | Chart notes and specialist evaluation | | FDA-labeled or guideline-supported indication | FDA label + prescriber letter citing guideline org |

If the peer-to-peer review results in an approval, confirm the approval in writing from BCBS and document the date and name of the approving reviewer. Keep this record in case of future disputes.